Quick Answer
HCW Biologics Inc. reported Diluted EPS of $10.63 per share (loss) for fiscal year 2025.
HCW Biologics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$10.63 | +65.7% |
| 2024 | -$30.96 | -4322.9% |
| 2023 | -$0.70 | -66.7% |
| 2022 | -$0.42 | +39.1% |
| 2021 | -$0.69 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.02 | +51.1% | +70.3% |
| June 30, 2025 | -$6.79 | +58.0% | -13480.0% |
| March 31, 2025 | -$0.05 | +75.0% | +98.8% |
| September 30, 2024 | -$4.13 | -2850.0% | +74.4% |
| June 30, 2024 | -$16.16 | -13366.7% | -7980.0% |
| March 31, 2024 | -$0.20 | -42.9% | -42.9% |
| September 30, 2023 | -$0.14 | -27.3% | -16.7% |
| June 30, 2023 | -$0.12 | -20.0% | +14.3% |
- HCW Biologics Inc. showed an increase of +65.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, HCW Biologics Inc.’s diluted eps has declined by 1440.6% (from $0.69 per share (loss) to $10.63 per share (loss)).
- The most recent figure is from HCW Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: